Fibroblast and Adjuvant Therapy for Lung Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 and ARDS lack effective methods to dampen excessive inflammatory responses and accelerate lung tissue regeneration, leading to high mortality rates and respiratory failure.
Innovation Solution
Administration of therapeutically effective amounts of fibroblasts and/or fibroblast-derived products, such as exosomes, along with specific adjuvants like peptides, toll-like receptor activators, chloroquine, and resveratrol, to modulate immune responses and reduce inflammatory cytokines in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If supportive care including mechanical ventilation is provided to COVID-19 patients with ARDS, then patient survival is extended, but mortality rate remains high due to insufficient ability to dampen excessive inflammatory response
Solution Approach 1:
The patent uses fibroblasts as intermediary cells that mediate the therapeutic effect by dampening excessive inflammatory response and promoting lung tissue regeneration. These cells act as a bridge between the harmful cytokine storm and the protective therapeutic outcome, reducing inflammation while accelerating recovery of lung function.
Solution Approach 2:
The patent converts the harmful excessive inflammatory response (cytokine storm) into a beneficial therapeutic effect by using fibroblasts to modulate the immune response. The same inflammatory pathway that causes damage is redirected to promote tissue repair and regeneration through controlled activation of healing mechanisms.
2Use of energy by moving object
If mechanical ventilation is used to support respiratory function, then oxygenation is maintained, but lung tissue damage progresses due to lack of regenerative therapy
Solution Approach 1:
The patent applies preliminary action by administering fibroblasts early in the disease course to prevent further lung tissue damage before it becomes irreversible. The fibroblasts are introduced proactively to dampen inflammation and initiate regeneration before the lung tissue undergoes complete failure, thereby preventing rather than just treating the damage.
Solution Approach 2:
The patent enables self-service by using the patient's own fibroblast cells (or allogeneic fibroblasts) to perform the regenerative function that the damaged lung tissue can no longer accomplish. The introduced fibroblasts self-organize to promote healing, produce extracellular matrix, and stimulate endogenous repair mechanisms without requiring external mechanical intervention for the regenerative process.
3Ease of operation
If no specific anti-inflammatory therapy is administered, then treatment simplicity is maintained, but excessive cytokine storm leads to organ failure and death
Solution Approach 1:
The patent applies parameter changes by modifying the immune response parameters through fibroblast administration. The fibroblasts change the quantitative and qualitative parameters of the inflammatory response, shifting the balance from excessive pro-inflammatory cytokine production to a more controlled state that allows tissue repair while maintaining immune surveillance.
Data Source
AI summary
Embodiments of the disclosure concern methods and compositions of treating or preventing viral infection, including of SARS-CoV-2, for example. In specific embodiments, one or more adjuvants are delivered to an individual receiving and/or having received fibroblasts and/or fibroblast-derived exosomes. In specific cases, the adjuvants comprise particular peptides, chloroquine and/or hydroxychloroquine, and/or one or more activators of one or more toll like receptors.